Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 4/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30231023 | 0.88 | GAA (0.45) | NLRP3POLBHTTKMT2A | |
| SCHEMBL24077148 | 0.88 | GAA (0.45) | NLRP3POLBHTTKMT2A | |
| SCHEMBL24077036 | 0.84 | NLRP3 (0.49) | NLRP3POLBHTT | |
| SCHEMBL24077178 | 0.84 | NLRP3 (0.46) | NLRP3ALOX15POLBRAB9ATSHR | |
| SCHEMBL24077142 | 0.82 | NLRP3 (0.45) | NLRP3ALOX15POLBRAB9ATSHR | |
| SCHEMBL24076292 | 0.81 | NLRP3 (0.46) | NLRP3ALOX15POLBRAB9ATSHR | |
| SCHEMBL24077179 | 0.81 | NLRP3 (0.49) | NLRP3ALOX15RAB9ATSHRSLC22A12 | |
| SCHEMBL24077027 | 0.79 | NLRP3 (0.45) | NLRP3ALOX15POLBRAB9ATSHR | |
| SCHEMBL25749329 | 0.79 | NLRP3 (0.46) | NLRP3ALOX15MAPTKMT2A | |
| SCHEMBL25746221 | 0.78 | RAB9A (0.52) | NLRP3ALOX15POLBRAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230202989-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021239885-A1 | COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202989-A1 | COMPOUNDS | NLRP3, NLRP1, IL1B | NLRP3 1/4885ALOX15 289/4885POLB 3231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.